On Jul. 26, 2020, Moderna announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for an additional commitment of up to $472 million to support late stage clinical development including the expanded Phase 3 study of the Companyﾒs mRNA vaccine candidate (mRNA-1273) against COVID-19.

Under the terms of the revised contract, BARDA is expanding their support of the Companyﾒs late stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. The total value of the award was approximately $955 million.